BioSpace News Archive

ALPS Pharmaceutical Ind. Co., Ltd. announced the launch of a water-soluble Quercetin delivery composition, Eubioflavonoid® derived from Sophora Japonica, which delivers more Quercetin to the body in a smaller dose.

Amgen announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed TEZSPIRE™ demonstrated reductions in the annualized asthma exacerbation rate across biomarker subgroups of patients with severe asthma.

Detailed results from a Phase 3 trial showed that adding Dupixent® to standard-of-care antihistamines significantly reduced itch and hives at 24 weeks in biologic-naïve patients with chronic spontaneous urticaria compared to antihistamines alone in this investigational setting.

ALPS Pharmaceutical Ind. Co., Ltd., a global pharmaceutical company that pioneered the use of phytochemicals in medicine and food, announced the launch of a new Isoquercetin composition, Eubio®Isoquercetin.

Hansa Biopharma AB announces that its first-in-class treatment Idefirix® has been granted early access post marketing authorization in France by French HAS for use in the desensitization of highly sensitized adult patients prior to kidney transplant, in accordance with the patient population specified in the Marketing Authorization received from the European Medicines Agency.

Positive detailed results from a second Phase 3 trial showed that Dupixent® 300 mg weekly significantly improved the signs and symptoms of eosinophilic esophagitis at 24 weeks compared to placebo in patients 12 years and older.